Search
Research
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)Pneumococcal disease (PD) remains a major health concern globally. In children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ and public health important serotypes 22F and 33F. This phase 3 study evaluated safety and immunogenicity of mixed PCV13/V114 regimens using a 3 + 1 dosing schedule when changing from PCV13 to V114 at doses 2, 3, or 4.
Research
The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old FoeStaphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%-30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection.
Research
Status epilepticus following vaccination in children aged ≤24 months: A five-year retrospective observational studyStatus epilepticus is associated with significant morbidity and mortality. While vaccine-proximate status epilepticus (VP-SE) has rarely been associated with cases of Dravet syndrome, it is not known whether VP-SE differs clinically from non-vaccine proximate status epilepticus (NVP-SE).
Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au The Vaccine Trials Group
The CHIP Study investigates how burn injuries in children affect their immune system.
CMVictory: finding a vaccine for cytomegalovirus, a serious virus for unborn babies
The year 2020 has been marked by possibly the greatest health challenge to face modern society. The emergence of COVID-19 as a novel human pathogen
To improve the health of the community through immunisation and prevention of infectious diseases, we are conducting clinical trials of vaccines.
Allergies have been on the rise in Australia over the past 20 years, with three out of every 10 babies born each year now developing a food-related
Māori and Pacific governance groups discuss and inform study protocols and issues that have arisen during the study, particularly those pertaining to Māori and Pacific ARF patients and their whānau.